MEDX HEALTH CORP (MDX.CA) Stock Price & Overview
TSX-V:MDX • CA5850901037
Current stock price
The current stock price of MDX.CA is 0.06 CAD. Today MDX.CA is down by 0%. In the past month the price increased by 9.09%. In the past year, price decreased by -7.69%.
MDX.CA Key Statistics
- Market Cap
- 19.676M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.02
- Dividend Yield
- N/A
MDX.CA Stock Performance
MDX.CA Stock Chart
MDX.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to MDX.CA. When comparing the yearly performance of all stocks, MDX.CA is a bad performer in the overall market: 70.69% of all stocks are doing better.
MDX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MDX.CA. MDX.CA may be in some trouble as it scores bad on both profitability and health.
MDX.CA Earnings
MDX.CA Forecast & Estimates
9 analysts have analysed MDX.CA and the average price target is 0.29 CAD. This implies a price increase of 376% is expected in the next year compared to the current price of 0.06.
For the next year, analysts expect an EPS growth of -50.36% and a revenue growth 14.21% for MDX.CA
MDX.CA Groups
Sector & Classification
MDX.CA Financial Highlights
Over the last trailing twelve months MDX.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -54.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -422.39% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MDX.CA Ownership
MDX.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| PRN | PROFOUND MEDICAL CORP | N/A | 329.876M | ||
| TLT | THERALASE TECHNOLOGIES INC | N/A | 65.55M | ||
| PINK | PERIMETER MEDICAL IMAGING AI | N/A | 46.548M | ||
| MIR | MEDMIRA INC | N/A | 45.499M | ||
| CNVI | CONAVI MEDICAL CORP | N/A | 40.879M | ||
| ASG | AURORA SPINE CORP | N/A | 21.236M | ||
| VPT | VENTRIPOINT DIAGNOSTICS LTD | N/A | 18.766M | ||
| NSCI | NANALYSIS SCIENTIFIC CORP | N/A | 17.999M | ||
| THRM | THERMA BRIGHT INC | N/A | 3.693M | ||
| VVTM | VVT MED INC | N/A |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About MDX.CA
Company Profile
MedX Health Corp. engages in the development, manufacture, and sale of medical device and software. The company is headquartered in Mississauga, Ontario. The company went IPO on 2008-02-12. The company develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. The company focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.
Company Info
IPO: 2008-02-12
MEDX HEALTH CORP
1495 Bonhill Road, Unit # 1 Mississauga
Mississauga ONTARIO L5T 1M2 CA
CEO: Scott Spearn
Employees: 0
Phone: 18883633112
MEDX HEALTH CORP / MDX.CA FAQ
What does MDX do?
MedX Health Corp. engages in the development, manufacture, and sale of medical device and software. The company is headquartered in Mississauga, Ontario. The company went IPO on 2008-02-12. The company develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. The company focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.
Can you provide the latest stock price for MEDX HEALTH CORP?
The current stock price of MDX.CA is 0.06 CAD.
Does MDX stock pay dividends?
MDX.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MDX stock?
MDX.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting MDX stock to perform?
9 analysts have analysed MDX.CA and the average price target is 0.29 CAD. This implies a price increase of 376% is expected in the next year compared to the current price of 0.06.
Can you provide the growth outlook for MEDX HEALTH CORP?
The Revenue of MEDX HEALTH CORP (MDX.CA) is expected to grow by 14.21% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.